Guardian Pharmacy Q4 revenue rises, company lifts 2026 EBITDA outlook
Overview
U.S. long-term care pharmacy's Q4 revenue grew 17% yr/yr, beating analyst expectations
Adjusted EPS for Q4 rose to $0.37, with net income up 81% yr/yr
Outlook
Guardian raises 2026 Adjusted EBITDA outlook to $120 mln-$124 mln from $115 mln-$118 mln
Company maintains 2026 revenue guidance at $1.40 bln-$1.42 bln
Result Drivers
ORGANIC GROWTH - Co said 12% organic revenue growth and a 10% increase in residents served contributed to Q4 results
OPERATIONAL IMPROVEMENTS - Profitability improved due to stronger purchasing, reimbursement, and labor economics, per co
FAVORABLE PAYOR DYNAMICS - Co said part of Q4 upside reflected favorable payor dynamics and quarter-to-quarter variability
Company press release: ID:nBw4ZHPmTa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $397.6 mln | $389.15 mln (3 Analysts) |
Q4 Adjusted EPS |
| $0.37 |
|
Q4 EPS |
| $0.33 |
|
Q4 Net Income |
| $21.3 mln |
|
Q4 Adjusted EBITDA |
| $39.5 mln |
|
Q4 Gross Profit |
| $85.5 mln |
|
Q4 Operating Income |
| $30.76 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for Guardian Pharmacy Services Inc is $35.00, about 4% above its March 10 closing price of $33.65
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 33 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
